Skip To Main Content
Andrew Spencer on Muck Rack

Andrew Spencer

As seen in: CNN, CNN en Español, Nature, Wiley Online Library, DZone, medRxiv, East Idaho News, Texas Medical Center, OncLive, Cancer Therapy Advisor and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Andrew

Contact Andrew, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Impact of socioeconomic status on treatment and survival in multiple myeloma in Australia

|
By Betty Gration, Cameron Wellard, Elizabeth Moore, Peter Mollee, Anita Shetty, Cecily J. Forsyth, Ian Kerridge, Zoe K. McQuilten, Erica Wood, Andrew Spencer, Georgia McCaughan, Jessica Heenan
| Nature Verified
Abstract Outcomes in multiple myeloma (MM) have improved significantly but remain heterogeneous. We assessed the impact of non-biological social determinants of health on treatment and survival outcomes in Australia using data from the Australian and New Zealand Myeloma and Related Diseases Registry. A total of 4405 patients diagnosed with MM between June 2012 and October 2025 across 44 Australian sites were assigned an area-level socioeconomic status (SES) using individual postcodes.
Open in Who Shared Issue with article?

FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial

|
By Adam Cohen, Joshua Richter, Suzanne Trudel, Alexander M. Lesokhin, Jacob P. Laubach, Sheeba K. Thomas, Simon Harrison, Luciano Costa Verified, Andrew Spencer, Rafael Fonseca, Peter Forsberg, Jesus G Berdeja, Rayan Kaedbey, Nizar Bahlis, Paula Rodríguez-Otero, Maria-Victoria Mateos, Tulika Tyagi, Divya Samineni, Wenyu Liu, Voleak Choeurng, James Cooper, Amrita Krishnan, Rin Nakamura, Chihunt Wong
| Nature Verified
Abstract Fc receptor-homolog 5 (FcRH5) is a membrane protein that is ubiquitously expressed on myeloma cells. Cevostamab is a first-in-class, FcRH5×CD3 bispecific antibody. GO39775 is a phase 1 dose-escalation and dose-expansion study evaluating fixed-duration cevostamab in relapsed or refractory multiple myeloma.
Open in Who Shared Issue with article?

Correction: Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody - Leukemia

|
By Marc S. Raab, Yael Cohen, Fredrik Schjesvold, Andrew Spencer, Martin Wermke, Anita Souza, Jonathan Kaufman, Enrique M. Ocio, Kristin Henson, Pierre-Eric Juif, John Blankenship, Serena De Vita
| Nature Verified
Correction to: Leukemia https://doi.org/10.1038/s41375-023-01883-3, published online 06 April 2023 In this article the wrong figure appeared as Fig. 3a; the figure should have appeared as shown below. The original article has been corrected. About this article Raab, M.S., Cohen, Y.C., Schjesvold, F. et al. Correction: Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody. Leukemia (2025).
Open in Who Shared Issue with article?
See all 14 licensed articles (20 Total)